Controls severe or incapacitating allergic conditions. ANDA 78988, held by Pharm Assoc. Prednisolone Sodium Phosphate.
As of Nov 16, 2026, ANDA 78988 (Prednisolone Sodium Phosphate), held by Pharm Assoc, was first approved by FDA on Jun 9, 2008, with 2 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Prednisolone Sodium Phosphate Oral Solution (20 mg prednisolone base per 5 mL) is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 9, 2008 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Prednisolone Sodium PhosphateEQ 20MG BASE/5ML · solution;oral | Prednisolone Sodium Phosphate | Rx |
| Jun 5, 2024 | Supplement 11Labeling · Standard review | Approved | None posted |
| Mar 24, 2010 | Supplement 5Labeling | Approved | None posted |
| Jun 9, 2008 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters